Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Summary

This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.

Timeline

Start

2021-08-16

Primary completion

2025-05

Completion

2025-05

Drugs

Indications